D.E. Shaw & Co
IPSC icon

D.E. Shaw & Co’s Century Therapeutics IPSC Stock Holding History

D.E. Shaw & Co’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,437
Closed -$282K – 5532
2022
Q1 		$282K Buy
22,437
+7,400
+49% +$98.1K ﹤0.01% 4684
2021
Q4 		$238K Sell
15,037
-5,819
-28% -$109K ﹤0.01% 4795
2021
Q3 		$525K Buy
+20,856
New +$565K ﹤0.01% 4059

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

D.E. Shaw & Co's IPSC Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Century Therapeutics (IPSC) in Q2 2022, closing a stake of 22,437 shares — an estimated $282K sold.

D.E. Shaw & Co first reported a position in IPSC in Q3 2021 and held it in 3 quarters. The position peaked at $525K in Q3 2021. 56 funds tracked by Wall St. Rank hold IPSC as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Century Therapeutics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 22,437 Century Therapeutics shares in Q2 2022, an estimated $282K.
  • D.E. Shaw & Co first reported a position in Century Therapeutics in Q3 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Century Therapeutics position peaked at $525K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.